MHLW to Present Estimate on Coverage Removal of OTC-Like Meds at 3-Party Talks
To read the full story
Related Article
- Topic of OTC-Like Drugs Dropped from 3-Party Talks: Ishin
May 27, 2025
- Impact of Nationwide Implementation of Regional Formularies “Difficult to Estimate”: MHLW Official
May 23, 2025
- OTC-Like Drug Is Hardest Topic in Tripartite Social Security Talks: Japan PM
May 22, 2025
- Regional Formulary Push Pops Up from Ishin at 3-Party Talks
May 16, 2025
- Ruling Bloc, Ishin Reach No Deal on Coverage of OTC-Like Drugs
May 8, 2025
- Ruling Coalition Wary of Scrapping Coverage for OTC-Like Drugs
April 21, 2025
- Medical Advocacy Group Condemns Plan to Remove Coverage for OTC-Like Drugs
April 17, 2025
- Scrap Coverage for OTC-Like Drugs with Same APIs and Dose as OTC Meds: Nippon Ishin
April 14, 2025
- 3-Party Talks Fail to Reach Specifics on OTC-Like Drugs
April 4, 2025
- Three-Party Talks to Be Held on Health Coverage of OTC-Like Drugs: Minister
March 4, 2025
REGULATORY
- LDP Pharma Study Group’s Final Proposal Urges Raising of Social Security Budget Ceiling
May 29, 2025
- LDP Fiscal Reform HQ’s Proposal Keeps Budget Ceiling Intact, but Urges Action on Wage Front
May 28, 2025
- Tap Consumption Tax Revenue to Ensure Stable Generic Supply: LDP League
May 28, 2025
- LDP Group Renews Call for Addition of MCI Screening to Health Checkups
May 28, 2025
- MOF Panel Again Presses for Expansion of CEA Scheme: “Spring” Proposal
May 27, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…